Merck Says FDA Accepts Its sBLA For Keytruda And Grants Priority Review

By: via Benzinga
Merck & Co., Inc. (NYSE: MRK) said the FDA has accepted its supplemental Biologics License Application (sBLA) for its Keytruda, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.